共 42 条
- [31] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077Mazieres, J.Duruisseaux, M.Curcio, H.Morizane, C.Galot, R.Rottey, S.Stratmann, J. A.Ma, Y.Bouzaggou, M.Geng, L.Wermke, M.
- [32] A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S647 - S647Dumbrava, E. E.Calvo, E.Garralda, E.Ryu, M. H.Oh, D. Y.Bai, L. Y.Chung, W.Rojas Laimito, K. I.Yildirim, O.Masciari, S.Kang, K.Buday, B.Rharbaoui, F.Abbadessa, G.Moreno Garcia, V.
- [33] A phase 1 dose escalation/expansion study of GSK5764227 (GSK'227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancersJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS847 - TPS847Saif, Wasif M.Cassier, Philippe AlexandreCurigliano, GiuseppeDaniele, GennaroHilton, John FrederickKoganemaru, ShigehiroKowalyszyn, RubenLorusso, PatriciaMoreno, VictorOlmedo Garcia, Maria EugeniaPerroud, Herman AndresSymeonides, Stefan N.Yamamoto, NoboruAziez, AmineAnjum, RanaLamacchia, JohnSembhi, HarjeetRatia, NiravItaliano, Antoine
- [34] First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutationANNALS OF ONCOLOGY, 2023, 34 : S468 - S468Heymach, J.Kotecki, N.Prenen, H.Alonso, G.Lindsay, C. R.Barve, M.Thamer, C.Eigenbrod-Giese, S.Marotti, M. A.Van Lancker, G.
- [35] DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomasCANCER RESEARCH, 2024, 84 (07)Capdevila, JaumeVandamme, TimonNiccoli, PatriciaMishima, SaoriKato, KenMa, YiyuanSun, PingGeng, LijiangLauer, Ulrich M.
- [36] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumorsCANCER RESEARCH, 2024, 84 (07)Cheng, YingLisberg, AaronLemech, CharlotteAbed, AfafChaudhry, ArvindSchmidt, AndrewLu, XinZhu, ZhongyuanGu, WeiQiu, YangShi, RongZhang, Bin
- [37] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical StudyBLOOD, 2022, 140Wong, Sandy W.Bar, NoffarParis, LauraHofmeister, Craig C.Hansson, MarkusSantoro, ArmandoMateos, Maria-VictoriaRodriguez-Otero, PaulaLund, JohanEncinas, CristinaYee, Andrew J.Oriol, AlbertCerchione, Claudiode la Rubia, JavierFerstl, BarbaraCarlson, KristinaRibas, PazBermudez, AranchaBoss, Isaac W.Gaudy, AllisonLi, ShaoyiHsu, KevinGodwin, Colin D.Burgess, Michael R.San-Miguel, JesusCosta, Luciano J.
- [38] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Boissel, Nicolasde Botton, StephaneThomas, Xavier G.Rao, ErcoleBonnevaux, HeleneRubin-Carrez, ChantalGuerif, StephaneBeys, EricGosselin, AliceBauchet, Anne-LaureNovikov, ValeryFernandes, ElmaWiederschain, DmitriPalatinsky, Emanuel A.Hsu, KarlFraenkel, Paula Goodman
- [39] Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation StudyBLOOD, 2018, 132Topp, Max S.Duell, JohannesZugmaier, GerhardAttal, MichelMoreau, PhilippeLanger, ChristianKroenke, JanFacon, ThierryEinsele, HermannMunzert, Gerd
- [40] GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3ANNALS OF ONCOLOGY, 2021, 32 : S834 - S834Miller, J. S.Warlick, E. D.Wangen, R.Zorko, N.Hinderlie, P.Lewis, D.Vallera, D. A.Felices, M.